BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35274331)

  • 1. Postradioiodine Graves' management: The PRAGMA study.
    Perros P; Basu A; Boelaert K; Dayan C; Vaidya B; Williams GR; Lazarus JH; Hickey J; Drake WM; Crown A; Orme SM; Johnson A; Ray DW; Leese GP; Jones TH; Abraham P; Grossman A; Rees A; Razvi S; Gibb FW; Moran C; Madathil A; Žarković MP; Plummer Z; Jarvis S; Falinska A; Velusamy A; Sanderson V; Pariani N; Atkin SL; Syed AA; Sathyapalan T; Nag S; Gilbert J; Gleeson H; Levy MJ; Johnston C; Sturrock N; Bennett S; Mishra B; Malik I; Karavitaki N
    Clin Endocrinol (Oxf); 2022 Nov; 97(5):664-675. PubMed ID: 35274331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graves' Disease: Can It Be Cured?
    Wiersinga WM
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):29-38. PubMed ID: 30912336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
    Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
    J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
    Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
    Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
    [No Abstract]   [Full Text] [Related]  

  • 5. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
    Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.
    Schmidt M; Gorbauch E; Dietlein M; Faust M; Stützer H; Eschner W; Theissen P; Schicha H
    Thyroid; 2006 Mar; 16(3):281-8. PubMed ID: 16571091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
    Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
    Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.
    Wood LC; Ingbar SH
    J Clin Invest; 1979 Nov; 64(5):1429-36. PubMed ID: 91625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and immunological predictors of Graves' orbitopathy after radioiodine therapy of Graves' disease].
    Sheremeta MS; Bessmertnaya EG; Elfimova AR; Babaeva DM; Belovalova IM; Sviridenko NY
    Probl Endokrinol (Mosk); 2023 Nov; 69(5):16-24. PubMed ID: 37968948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is excessive weight gain after ablative treatment of hyperthyroidism due to inadequate thyroid hormone therapy?
    Tigas S; Idiculla J; Beckett G; Toft A
    Thyroid; 2000 Dec; 10(12):1107-11. PubMed ID: 11201857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
    Batra R; Krishnasamy SK; Buch H; Sandramouli S
    Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism.
    Sekulić V; Rajić M; Vlajković M; Ilić S; Stević M; Kojić M
    Ann Nucl Med; 2017 Dec; 31(10):744-751. PubMed ID: 28895066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
    Tallstedt L; Lundell G; Blomgren H; Bring J
    Eur J Endocrinol; 1994 May; 130(5):494-7. PubMed ID: 8180678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.